Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
MNPR Stock Chart & Stats
$56.08
-$0.61(-2.42%)
At close: 4:00 PM EST
$56.08
-$0.61(-2.42%)
Day’s Range― - ―
52-Week Range$28.40 - $105.00
Previous CloseN/A
Volume23.12K
Average Volume (3M)181.15K
Market Cap
$375.30M
Enterprise Value-$61.30B
Total Cash (Recent Filing)$61.83B
Total Debt (Recent Filing)$154.92M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding6,692,140
10 Day Avg. Volume158,601
30 Day Avg. Volume181,154
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.04
Enterprise Value/Market Cap-163.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda4.02K
Forecast
1Y Price Target
$111.00Price Target Upside97.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And MechanismPivotal study results showed meaningful copper mobilization with increased fecal copper excretion and sustained neurological benefit, which directly addresses earlier questions about the drug's ability to remove excess copper.
Commercial Readiness And Patient AdvocacyStrong patient and caregiver testimony, hiring of an experienced commercial and strategy officer, and sufficient cash reserves support preparation for a potential launch and highlight a meaningful commercial opportunity.
Regulatory OutlookAnalyst views ALXN-1840 as reaching the final regulatory stage toward potential approval and notes that FDA acceptance of a single well-controlled pivotal study could reduce the likelihood of a new large trial.
Bears Say
Adoption And Reimbursement PressurePhysician preference for cheaper standard therapies and reimbursement constraints may restrict use of ALXN-1840 to more severe patients, limiting broader market uptake despite unmet need.
Mechanism And Program History RiskThe original developer's inability to explain how the drug eliminated unbound copper and the program's prior termination create reputational and regulatory concerns about the mechanism of action.
Regulatory UncertaintyUncertainty remains about how the FDA will interpret the totality of data and the agency could request additional studies or engage in labeling negotiations, which would complicate or delay approval.
Monopar Therapeutics Inc News
MNPR FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $28.40 and its highest was $105.00 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Monopar Therapeutics Inc’s market cap is $375.30M.
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s upcoming earnings report date is May 07, 2026 which is in 24 days.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on Mar 27, 2026. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.481 by -$0.159.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 6,692,140 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.481. Following the earnings report the stock price went down -0.843%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Currently, no hedge funds are holding shares in MNPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monopar Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$111.00 (97.93% Upside)
$111.00 (97.93% Upside)
Blogger Sentiment
Bullish
MNPR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 135.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
75.96%
12-Months-Change
Fundamentals
Return on Equity
-0.04%
Trailing 12-Months
Asset Growth
133.40%
Trailing 12-Months
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
MNPR Stock 12 Month Forecast
Average Price Target
$111.00
▲(97.93% Upside)
Technical Analysis
Cardiff Oncology
―
Vanda
―
Verastem
―
Mereo Biopharma Group Plc
―
Silence Therapeutics
―